Literature DB >> 23095874

Recombinant allergens: the present and the future.

Marek Jutel1, Katarzyna Solarewicz-Madejek, Sylwia Smolinska.   

Abstract

Allergen specific immunotherapy (SIT) is the only known causative treatment of allergic diseases. Recombinant allergen-based vaccination strategies arose from a strong need to both to improve safety and enhance efficacy of SIT. In addition, new vaccines can be effective in allergies including food allergy or atopic dermatitis, which poorly respond to the current treatment with allergen extracts. A number of successful clinical studies with both wild-type and hypoallergenic derivatives of recombinant allergens vaccines have been reported for the last decade. They showed high efficacy and safety profile as well as very strong modulation of T and B cell responses to specific allergens.

Entities:  

Keywords:  allergen-specific immunotherapy; allergy; hypoallergens; recombinant allergens; vaccines

Mesh：

Substances：

Year:  2012        PMID： 23095874      PMCID： PMC3660775          DOI： 10.4161/hv.22064

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


  68 in total

1.  Allergen-specific immunotherapy with recombinant grass pollen allergens.

Authors:  Marek Jutel; Lothar Jaeger; Roland Suck; Hanns Meyer; Helmut Fiebig; Oliver Cromwell
Journal:  J Allergy Clin Immunol       Date:  2005-09       Impact factor: 10.793

2.  Treatment of cat allergy with T-cell reactive peptides.

Authors:  P S Norman; J L Ohman; A A Long; P S Creticos; M A Gefter; Z Shaked; R A Wood; P A Eggleston; K B Hafner; P Rao; L M Lichtenstein; N H Jones; C F Nicodemus
Journal:  Am J Respir Crit Care Med       Date:  1996-12       Impact factor: 21.405

3.  Panallergens and their impact on the allergic patient.

Authors:  Michael Hauser; Anargyros Roulias; Fátima Ferreira; Matthias Egger
Journal:  Allergy Asthma Clin Immunol       Date:  2010-01-18       Impact factor: 3.406

4.  Vaccination with genetically engineered allergens prevents progression of allergic disease.

Authors:  V Niederberger; F Horak; S Vrtala; S Spitzauer; M-T Krauth; P Valent; J Reisinger; M Pelzmann; B Hayek; M Kronqvist; G Gafvelin; H Grönlund; A Purohit; R Suck; H Fiebig; O Cromwell; G Pauli; M van Hage-Hamsten; R Valenta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

5.  Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination.

Authors:  M Focke; B Linhart; A Hartl; U Wiedermann; W R Sperr; P Valent; J Thalhamer; D Kraft; R Valenta
Journal:  Clin Exp Allergy       Date:  2004-10       Impact factor: 5.018

6.  Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man.

Authors:  Ines Pree; Jürgen Reisinger; Margit Focke; Susanne Vrtala; Gabrielle Pauli; Marianne van Hage; Oliver Cromwell; Elisabeth Gadermaier; Cornelia Egger; Norbert Reider; Friedrich Horak; Rudolf Valenta; Verena Niederberger
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

Review 7.  Pollen-food syndromes associated with weed pollinosis: an update from the molecular point of view.

Authors:  M Egger; S Mutschlechner; N Wopfner; G Gadermaier; P Briza; F Ferreira
Journal:  Allergy       Date:  2006-04       Impact factor: 13.146

8.  Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom.

Authors:  U Müller; C A Akdis; M Fricker; M Akdis; T Blesken; F Bettens; K Blaser
Journal:  J Allergy Clin Immunol       Date:  1998-06       Impact factor: 10.793

9.  Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.

Authors:  Gabrielle Pauli; Tina H Larsen; Sabina Rak; Friedrich Horak; Elide Pastorello; Rudolf Valenta; Rudolph Valenta; Ashok Purohit; Monica Arvidsson; Alexander Kavina; Jan W Schroeder; Nadine Mothes; Susanne Spitzauer; Armelle Montagut; Sylvie Galvain; Michel Melac; Claude André; Lars K Poulsen; Hans-Jorgen Malling
Journal:  J Allergy Clin Immunol       Date:  2008-11       Impact factor: 10.793

Review 10.  Latex-fruit syndrome.

Authors:  Carlos Blanco
Journal:  Curr Allergy Asthma Rep       Date:  2003-01       Impact factor: 4.919
View more
  9 in total

1.  Cloning, expression, and analysis of a cDNA coding for the Dermatophagoides farinae group 21 (Der f 21) allergen.

Authors:  Yubao Cui; Yongqian Jiang; Youlin Ji; Ying Zhou; Lili Yu; Nan Wang; Li Yang; Chengbo Zhang
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

Review 2.  Molecular biomarkers for grass pollen immunotherapy.

Authors:  Florin-Dan Popescu
Journal:  World J Methodol       Date:  2014-03-26

3.  Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).

Authors:  Oliver Pfaar; Claus Bachert; Albrecht Bufe; Roland Buhl; Christof Ebner; Peter Eng; Frank Friedrichs; Thomas Fuchs; Eckard Hamelmann; Doris Hartwig-Bade; Thomas Hering; Isidor Huttegger; Kirsten Jung; Ludger Klimek; Matthias Volkmar Kopp; Hans Merk; Uta Rabe; Joachim Saloga; Peter Schmid-Grendelmeier; Antje Schuster; Nicolaus Schwerk; Helmut Sitter; Ulrich Umpfenbach; Bettina Wedi; Stefan Wöhrl; Margitta Worm; Jörg Kleine-Tebbe; Susanne Kaul; Anja Schwalfenberg
Journal:  Allergo J Int       Date:  2014

Review 4.  Allergen-Specific Immunotherapy in Asthma.

Authors:  Marek Jutel
Journal:  Curr Treat Options Allergy       Date:  2014-03-12

Review 5.  Allergen Immunotherapy: Past, Present, and Future.

Authors:  Marek Jutel; Anna Kosowska; Sylwia Smolinska
Journal:  Allergy Asthma Immunol Res       Date:  2016-05       Impact factor: 5.764

Review 6.  A review of clinical efficacy, safety, new developments and adherence to allergen-specific immunotherapy in patients with allergic rhinitis caused by allergy to ragweed pollen (Ambrosia artemisiifolia).

Authors:  Mirjana Turkalj; Ivana Banic; Srdjan Ante Anzic
Journal:  Patient Prefer Adherence       Date:  2017-02-14       Impact factor: 2.711

Review 7.  Molecular allergy diagnostic tests: development and relevance in clinical practice.

Authors:  J Kleine-Tebbe; U Jappe
Journal:  Allergol Select       Date:  2017-08-04

Review 8.  Egg Allergy: Diagnosis and Immunotherapy.

Authors:  Dulashi Withanage Dona; Cenk Suphioglu
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 9.  Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy.

Authors:  Katharina Marth; Margarete Focke-Tejkl; Christian Lupinek; Rudolf Valenta; Verena Niederberger
Journal:  Curr Treat Options Allergy       Date:  2014-02-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.